āThe circulation of more transmissible recent variants of the SARS-CoV-2 virus has led to surges in COVID-19 cases. The majority of COVID-19 hospitalizations and deaths are occurring in unvaccinated individuals. The emergence of the Omicron variant further demonstrates the importance of vaccination, boosters, and other prevention efforts, including testing and masking, to protect eligible individuals (patients/residents), staff, and the community from COVID-19.
This AFL reminds facilities of the importance of offering and encouraging COVID-19 vaccinations, including booster doses, to clinically eligible individuals, especially those at highest risk of morbidity and mortality, at all interactions across the healthcare continuum. The following three vaccines are authorized for use in the United States:
- Pfizer-BioNTech
- Moderna
- Johnson and Johnson [J&J]/Janssen.
The COVID-19 mRNA vaccines from Pfizer-BioNTech and Moderna are preferred over the Janssen (J&J) COVID-19 vaccine. However, vaccination should not be delayed in order to offer a specific product.
COVID-19 booster doses help keep immunity strong and increase protection against COVID-19. Booster doses are especially urgent for those at higher risk of severe disease. COVID-19 boosters help broaden and strengthen the protection against the Omicron variant.
For assistance in obtaining future COVID-19 vaccinations and/or booster doses, clinically eligible individuals may be directed to the MyTurn or CDC Vaccines websites.
Additionally, for any facilities not already providing COVID-19 vaccines that are interested in becoming a COVID-19 vaccine provider, please visit myCAvax. For COVID-19 vaccine provider enrollment instructions, please visit California COVID-19 Vaccination Programs.
If you have any questions about this AFL, please contact the Healthcare-Associated Infections Program at HAIProgram@cdph.ca.gov.
Sincerely,
Original signed by Cassie Dunham
Cassie Dunham
Acting Deputy Director
Resources: